Press Releases

Date	Title
April 21, 2020	Outlook Therapeutics Bolsters Clinical and Commercial Expertise with Two Key Appointments to Board of Directors Internationally renowned ophthalmologist, Gerd Auffarth , MD, ranked as one of the “100 most influential personalities in ophthalmology worldwide" in the 2020 Power List published by The Ophthalmologist magazine Julian Gangolli , former President of the North American Pharmaceutical division of
April 15, 2020	Outlook Therapeutics to Present at the April 2020 Virtual Investor Summit Presentation with live audio webcast on Wednesday, April 22 at 10:30 AM ET, immediately followed by an interactive Q&A session CRANBURY, N.J. , April 15, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to
April 14, 2020	Outlook Therapeutics Provides COVID-19 Impact Update on Ongoing Clinical Trials NORSE 1 and NORSE 2 Company reports no anticipated COVID-19 impact on NORSE 1, its first registration clinical trial evaluating ONS-5010, an investigational ophthalmic formulation of bevacizumab, to treat wet AMD Risk mitigation strategies being developed for possible one- to three-month delay related to COVID-19
March 5, 2020	Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved Outlook Therapeutics intends to market ONS-5010 as LYTENAVA ™ (bevacizumab-vikg), if approved. LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two registration clinical trials (NORSE 1 and NORSE 2) to treat wet
February 26, 2020	Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market CRANBURY, N.J. , Feb. 26, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
February 24, 2020	Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market CRANBURY, N.J. , Feb. 24, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
February 14, 2020	Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020 First clinical trial results from the Phase 3 development program for ONS-5010 expected in six months CRANBURY, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA
February 4, 2020	Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference CRANBURY, N.J. , Feb. 04, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it is
January 28, 2020	Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010 CRANBURY, N.J. , Jan. 28, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has
December 26, 2019	Outlook Therapeutics Announces Completion of Warrant Restructuring CRANBURY, N.J. , Dec. 26, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA -approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has